Da	te: Apr. 11 <sup>th</sup> , 2021								
	ur Name: Qiqi Zhang								
	Manuscript Title:Prognostic significance of Pyruvate kinase M2 expression in esophageal squamous cell carcinoma and its meta-analysis								
cai	carcinoma and its meta-analysis Manuscript number (if known):TCR-21-442								
IVI	Manuscript number (if known):ICR-21-442								
rel pa to rel Th ma Th to me	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, e following questions apply anuscript only.  e author's relationships/act the epidemiology of hypertedication, even if that medication.	manuscript. "Related" means affected by the content of the author's relationship in the content of the content	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertainally all relationships with manufacturers of antihypertensives.	ins re					
		Name all entities with	Specifications/Comments						
		whom you have this	(e.g., if payments were made to you or to your						
		relationship or indicate	institution)						
		none (add rows as							
		needed)							
		Time frame: Since the initia	planning of the work						
1	All support for the present manuscript (e.g., funding,	XNone							
	provision of study materials,								
	medical writing, article								
	processing charges, etc.)								
	No time limit for this item.								
		Time frame: past	36 months						
2	Grants or contracts from	XNone							
	any entity (if not indicated in item #1 above).								
3	Royalties or licenses	X None							
3	Noyalties of licelises								
4	Consulting fees	XNone							

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_XNone	
6	Payment for expert testimony	_XNone	
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or	_XNone	
	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy	_XNone	
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options	XNOTIE	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_XNone	
13	Other financial or non- financial interests	XNone	
Ple	ease summarize the above c	onflict of interest in the fo	ellowing box:

None.		

Da	te: Apr. 11 <sup>th</sup> , 2021		
Yo	ur Name: Shutao Zhe	eng	
Ma	nuscript Title:Prognos	tic significance of Pyruvate	kinase M2 expression in esophageal squamous cell
car	cinoma and its meta-analys	is	
Ma	nuscript number (if known)	:TCR-21-442	
relator	ated to the content of your ries whose interests may be transparency and does not ationship/activity/interest,	manuscript. "Related" mea e affected by the content on necessarily indicate a bias. it is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so.  ps/activities/interests as they relate to the current
to me	the epidemiology of hypertodication, even if that medic	ension, you should declare cation is not mentioned in t pport for the work reporte	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.  d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	l planning of the work
	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
)	Grants or contracts from	X None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	X None	
	,		
	Consulting fees	X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_XNone	
6	Payment for expert testimony	_XNone	
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or	_XNone	
	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy	_XNone	
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options	XNOTIE	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_XNone	
13	Other financial or non- financial interests	XNone	
Ple	ease summarize the above c	onflict of interest in the fo	ellowing box:

None.		

Da	te: Apr. 11 <sup>th</sup> , 2021								
Yo	ur Name: Qing Liu _								
	Manuscript Title:Prognostic significance of Pyruvate kinase M2 expression in esophageal squamous cell carcinoma and its meta-analysis								
cai	carcinoma and its meta-analysis Manuscript number (if known):TCR-21-442								
Ma	Manuscript number (if known):TCR-21-442								
rel pa to rel Th ma Th to me	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, e following questions apply anuscript only.  e author's relationships/act the epidemiology of hypertedication, even if that medication.	manuscript. "Related" means affected by the content of the author's relationship in the content of the content	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertai all relationships with manufacturers of antihypertensiv	e					
		Name all entities with	Specifications/Comments						
		whom you have this relationship or indicate	(e.g., if payments were made to you or to your institution)						
		none (add rows as	institution						
		needed)							
		Time frame: Since the initia	planning of the work						
1	All support for the present	X None							
	manuscript (e.g., funding,								
	provision of study materials,								
	medical writing, article								
	processing charges, etc.)								
	No time limit for this item.								
		Time frame: past	36 months						
2	Grants or contracts from	XNone							
	any entity (if not indicated in item #1 above).								
2	,	V None							
3	Royalties or licenses	XNone							
4	Consulting fees	XNone							

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_XNone	
6	Payment for expert testimony	_XNone	
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or	_XNone	
	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy	_XNone	
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options	XNOTIE	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_XNone	
13	Other financial or non- financial interests	XNone	
Ple	ease summarize the above c	onflict of interest in the fo	ellowing box:

None.		

Dat	te: Apr. 11 <sup>th</sup> , 2021			
	ır Name: Tao Liu			
Ма	nuscript Title:Prognost	tic significance of Pyruvat	e kinase M2 expression in esophageal squamous cell	
car	cinoma and its meta-analys	is		
rela par to t	ated to the content of your ties whose interests may be	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.	
	e following questions apply nuscript only.	to the author's relationsh	ips/activities/interests as they relate to the current	
to t	•	ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript pertain e all relationships with manufacturers of antihypertensive the manuscript.	
	tem #1 below, report all su time frame for disclosure i	•	ed in this manuscript without time limit. For all other iten	ns,
	· •	•	ed in this manuscript without time limit. For all other item  Specifications/Comments	ns,
	· •	s the past 36 months.		ns,
	· •	s the past 36 months.  Name all entities with	Specifications/Comments	ns,
	· •	Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your	ns,
	· •	Name all entities with whom you have this relationship or indicate	Specifications/Comments (e.g., if payments were made to you or to your	ns,
	· •	Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)	ms,
	· •	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	ms,
	All support for the present manuscript (e.g., funding,	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)	ns,
	All support for the present manuscript (e.g., funding, provision of study materials,	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)	ms,
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)	ms,
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)	ms,
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)	ns,
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)	ns,
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initialXNone	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work	ns,
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initialXNone	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work	ns,
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initialXNone	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work	ns,
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initialXNone	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work	ms,
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initialXNone  Time frame: pasXNone	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work	ms,
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initialXNone	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work	ms,

Consulting fees

X\_\_None

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_XNone	
6	Payment for expert testimony	_XNone	
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or	_XNone	
	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy	_XNone	
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options	XNOTIE	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_XNone	
13	Other financial or non- financial interests	XNone	
Ple	ease summarize the above c	onflict of interest in the fo	ellowing box:

None.		

	te: Apr. 11 <sup>th</sup> , 2021		
Ma ca	rcinoma and its meta-analys	tic significance of Pyruvate	e kinase M2 expression in esophageal squamous cell
rel pa to rel	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest,	manuscript. "Related" me e affected by the content necessarily indicate a bias it is preferable that you d	
	e following questions apply anuscript only.	to the author's relationsh	ips/activities/interests as they relate to the current
to me	the epidemiology of hypertoedication, even if that medic	ension, you should declare ation is not mentioned in pport for the work reporte	e defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.  ed in this manuscript without time limit. For all other items,
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as needed)	
		Time frame: Since the initia	al planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: pas	t 26 months
)	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
<b>,</b>	Royalties or licenses	XNone	
	Consulting fees	X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_XNone	
6	Payment for expert testimony	_XNone	
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or	_XNone	
	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy	_XNone	
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options	XNOTIE	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_XNone	
13	Other financial or non- financial interests	XNone	
Ple	ease summarize the above c	onflict of interest in the fo	ellowing box:

None.		

Da	te: Apr. 11 <sup>th</sup> , 2021					
	ur Name: Lifei Yang _					
Manuscript Title:Prognostic significance of Pyruvate kinase M2 expression in esophageal squamous cell						
Carcinoma and its meta-analysis Manuscript number (if known):TCR-21-442						
Ma	Manuscript number (if known):TCR-21-442					
relipantor relimator The ma	ated to the content of your rties whose interests may be transparency and does not reationship/activity/interest, ationship/activity/interest, ationship questions apply inuscript only.  The author's relationships/activity epidemiology of hyperteredication, even if that medication,	manuscript. "Related" me e affected by the content onecessarily indicate a biasit is preferable that you do to the author's relationship ivities/interests should be ension, you should declare action is not mentioned in poort for the work reported.	ips/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive			
		Name all angles and the	Considerational Community			
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your			
		relationship or indicate	institution)			
		none (add rows as	satuation,			
		needed)				
		Time frame: Since the initia	I planning of the work			
1	All support for the present	X None				
	manuscript (e.g., funding,					
	provision of study materials,					
	medical writing, article					
	processing charges, etc.)					
	No time limit for this item.					
		Time frame: past	t 36 months			
2	Grants or contracts from	XNone				
	any entity (if not indicated					
	in item #1 above).					
3	Royalties or licenses	XNone				
1	Consulting fees	Y None				

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_XNone	
6	Payment for expert testimony	_XNone	
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or	_XNone	
	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy	_XNone	
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options	XNOTIE	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_XNone	
13	Other financial or non- financial interests	XNone	
Ple	ease summarize the above c	onflict of interest in the fo	ellowing box:

None.		

	te: Apr. 11 <sup>th</sup> , 2021 ur Name: Xiujuan Har		
Ma ca	anuscript Title:Prognost	tic significance of Pyruvate	e kinase M2 expression in esophageal squamous cell
rel pa to rel	ated to the content of your ries whose interests may be transparency and does not ationship/activity/interest, e following questions apply	manuscript. "Related" me e affected by the content necessarily indicate a bias it is preferable that you d	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.  ips/activities/interests as they relate to the current
Th	•	ension, you should declare	e defined broadly. For example, if your manuscript pertains a all relationships with manufacturers of antihypertensive the manuscript.
	item #1 below, report all su e time frame for disclosure i	•	ed in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_XNone	
6	Payment for expert testimony	_XNone	
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or	_XNone	
	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy	_XNone	
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options	XNOTIE	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_XNone	
13	Other financial or non- financial interests	XNone	
Ple	ease summarize the above c	onflict of interest in the fo	ellowing box:

None.		

Da	ite: Apr. 11 <sup>th</sup> , 2021								
Yo	ur Name: Xiaomei Lu								
M	anuscript Title:Prognos	tic significance of Pyruvate	e kinase M2 expression in esophageal squamous cell						
M	carcinoma and its meta-analysis Manuscript number (if known):TCR-21-442								
rel pa to rel	lated to the content of your rties whose interests may be transparency and does not lationship/activity/interest,	manuscript. "Related" me e affected by the content necessarily indicate a bias it is preferable that you d							
	e following questions apply anuscript only.	to the author's relationsh	ips/activities/interests as they relate to the current						
to	•	ension, you should declare	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.						
	item #1 below, report all su e time frame for disclosure i	• •	ed in this manuscript without time limit. For all other items,						
		Name all entities with	Specifications/Comments						
		whom you have this	(e.g., if payments were made to you or to your						
		relationship or indicate	institution)						
		none (add rows as							
		needed)							
		Time frame: Since the initia	al planning of the work						
	All support for the present	X None	8						
-	manuscript (e.g., funding,	XNone							
	provision of study materials,								
	medical writing, article								
	processing charges, etc.)								
	No time limit for this item.								
		Time frame: nee	t 26 months						
	Charte an equition to fire	Time frame: pas	t 50 months						
-	Grants or contracts from	XNone	<u> </u>						
	any entity (if not indicated								
	in item #1 above).	V Nove							
5	Royalties or licenses	XNone							
1	Consulting fees	X None							
г	L CONSUMING ICCS	A NOTIC							

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_XNone	
6	Payment for expert testimony	_XNone	
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or	_XNone	
	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy	_XNone	
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options	XNOTIE	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_XNone	
13	Other financial or non- financial interests	XNone	
Ple	ease summarize the above c	onflict of interest in the fo	ellowing box:

None.		